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Background: This study was performed to assess angiographic outcomes of newer
generation drug-eluting stent [everolimus-(EES) or resolute zotarolimus-eluting stents
(R-ZES)] for long or diabetic coronary artery disease. Angiographic efﬁcacy of EES
or R-ZES has not been sufﬁciently evaluated for long or diabetic coronary artery
disease.
Methods: Patients level data from three randomized trials (Long-DES III, IV and
ESSENCE-DIABETES I and II) were pooled to estimate angiographic efﬁcacy of
EES or R-ZES. A total of 750 patients underwent EES (n¼373) and R-ZES (n¼377).
We evaluated follow-up angiography.
Results: Baseline clinical and angiographic characteristics were well balanced. Stent
length was similar between two groups (35.2  14.9 mm vs. 35.9  14.4 mm,
p¼0.51). Follow-up angiography was done in 546 patients (287 [76.9%] in EES
patients and 259 [68.7%] in R-ZES patients). In-stent (2.4% vs. 3.1%, p¼0.64) and in-
segment restenosis (4.9% vs. 3.9%, p¼0.56) were statistically not different between
EES and R-ZES group. In-segment restenosis was similar between EES and R-ZES
group in diabetics (3.7% vs. 2.4%, p¼0.51), > 30 mm long stent implantation patients
(7.3% vs. 5.8%, p¼0.61), left anterior descending artery disease (3.3% vs. 3.0%,
p¼0.86), and  2.5 mm small vessel disease (6.8% vs. 3.5%, p¼0.43). The threshold
of stent length for predicting restenosis in overall patients was 37.8 mm (area under
the receiver-operating characteristic curve: 0.678, 95% conﬁdence interval: 0.637 to
0.717, p¼0.001), which had a sensitivity and speciﬁcity of 70.3% and 61.3%,
respectively.
Conclusions: EES and R-ZES showed comparable angiographic outcomes in patients
at high risk of restenosis and effectively reduced angiographic restenosis across all
high risk lesion subsets. The cut-off stent length for predicting angiographic restenosis
was 37.8 mm.P
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Background: There are limited data regarding the clinical outcomes of very long
stent implantations, particularly the use of second generation drug-eluting stents
(DES).
Methods: From the IRIS-DES Registry, we identiﬁed 822 patients who were
treated for coronary stenosis using  60 mm of overlapping drug-eluting stents. Of
these, 269, 137, and 416 patients were treated using cobalt chromium everolimus
eluting stent (CoCr-EES), platinum chromium everolimus-eluting stents (PtCr-EES)
or sirolimus-eluting stents (SES), respectively. Major adverse cardiac events
(MACE) were deﬁned using a composite measure consisting of death, myocardial
infarction (MI; periprocedural or spontaneous), or target vessel revascularization
(TVR).
Results: Per target lesion, the average stent number was 2.7  0.7 and the average
stent length was 76.3  14.8 mm. On 2-year clinical follow-up, the rate of MACE,
death, spontaneous MI, TVR, and stent thrombosis (deﬁnite or probable stent
thrombosis) were 21.7%, 4.2%, 1.9%, 7.7%, and 0.7%, respectively. Although 139
patients (16.9%) suffered from periprocedural MI, this was not independently asso-
ciated with death, spontaneous MI, or TVR (hazard ratio [HR], 1.29; 95% conﬁdence
interval [CI] 0.57–2.95, p ¼ 0.54). In addition, there were no statistical differences
between EES and SES implantation in terms of the adjusted risks of MACE (HR,
1.32; 95% CI 0.90–1.94, p ¼ 0.16).
Conclusions: When treating diffuse coronary stenosis, multiple overlapping stent
implantations using second generation DES appear to be equally safe and effective.
Although periprocedural MI frequently occurred, it was not associated with an
increase in long-term adverse clinical outcomes.JACC Vol 62/18/Suppl B j October 27–November 1, 2013 j TCT Abstr
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Background: Despite the extensive knowledge accrued on DES in the past years,
there is still lack of consistent data on the very late outcomes of these devices,
especially after 5 years of their implantation. We sought to provide the longest
clinical follow-up data on outcomes of unselected patients treated solely with
DES.
Methods: The DESIRE registry is a prospective, single-center registry encompassing
all consecutive patients treated solely with DES since May 2002. The primary goal is
the very long-term occurrence of MACE and stent thrombosis (ST). Patients were
clinically followed at 1, 6 and 12 months and then annually.
Results: A total of 4,790 patients were included. The mean age was 64  11 years.
DM was detected in 29.7% and 44.8% presented with acute coronary syndrome.
Follow-up was obtained in 98.5% of the patients (median 5.6 years). Currently, 79.6%
of the population is free of any MACE. TVR was performed in 5.3% of the patients.
Q-wave MI rate was only 1.7% while total ST rate was 1.9%. The majority of deﬁnite
ST cases occurred between the 1st and 3rd years. Independent predictors of MACE
were treatment of SVG (HR 1,63; 95% CI, 1.22 to 2.18, p¼ 0.001), multivessel
disease (HR 1.39; 95% CI, 1.03 to 1.87, p<0.001), residual stenosis (HR 1.3; 95% CI,
1.1 to 1.5, p¼ 0.034), DM (HR 1.6; 95% CI, 1.1 to 2.2, p¼ 0.006) and renal insuf-
ﬁciency (HR 1.5; 95% CI, 1.34 to 1.81, p¼ 0.004). Independent predictors of ST were
PCI for STEMI (HR 3.5; 95% CI, 1.3 to 9.4, p¼ 0.013), stent length (HR 1.8; 95% CI,
1.09 to 3.02, p¼0.023), moderate/severe calciﬁcation at lesion site (HR 2.38; 95% CI,
1.34 to 4.23, p¼0.003), and in-stent residual stenosis (HR 1.04; 95% CI, 1.01 to 1.06,
p¼0.003).
Conclusions: The DESIRE registry probably represents the longest FU of a real world
cohort treated solely with DES. In our single center experience, the use of DES was
associated with very long-term safety and effectiveness with acceptable low rates of
adverse clinical events, including ST. Also, there was no steady annual increment
in the occurrence of ST, with a marked decrease of this complication after the 3rd year
of FU.
TCT-210
Clinical Outcomes Following Resolute Zotarolimus-eluting Stent Implantation in
Diabetic versus Non-Diabetic Patients Suitable for Percutaneous Coronary
Revascularization: Insights From a Multicenter Italian Registry
Alfonso Ielasi1, Azeem Latib1, Francesco Burzotta2, Francesco Summaria3,
Maria De Vita4, Angelo Anzuini5, Claudio Larosa6, Francesco Della Rovere7,
Saverio Lanzone8, alessandro manzoli9, Francesca Giovannelli10, Antonio Colombo11
1San Raffaele Scientiﬁc Institute, Milan, Italy, 2Catholic University Hospital of the
Sacred Heart, Roma, Italy, 3Policlinico Casilino, Rome, Italy, 4Ospedale Morgagni-
Pierantoni, Forlì, Italy, 5Istituto Clinico Humanitas Mater Domini, Castellanza (VA),
Italy, 6Ospedale Bonomo, Andria (BAT), Italy, 7Ospedali Galliera, Genova, Italy,
8Ospedali di Venere, Carbonara (BA), Italy, 9S. Giovanni Hospital, Rome, Italy,
10Ospedale Sant'Andrea, Rome, Italy, 11EMO GVM Centro Cuore Columbus/San
Raffaele Hospital, Milan, Italy
Background: Diabetes mellitus remains a signiﬁcant predictor of adverse clinical
outcomes after percutaneous coronary intervention (PCI). Outcomes after 2nd
generation drug-eluting stent (DES) implantation in diabetics remains ill-deﬁned. Aim
of this study was to compare the clinical outcomes of the Resolute Zotarolimus-eluting
stent (R-ZES) in diabetic and non-diabetic patients.
Methods: From August 2008 to November 2010, patients with signiﬁcant coronary
artery stenosis suitable for PCI and successful implantation of at least one R-ZES were
included in a multicenter, prospective Italian database. Primary end-point of the study
was to assess the incidence of a composite of cardiac death, target lesion revascu-
larization (TLR) and myocardial infarction (MI) between diabetic and non-diabetic
patients and among diabetics between insulin (ITDM) and non insulin-treated
(NITDM).
Results: During the study period 1,216 patients (365 diabetics and 851 non-
diabetics)suitable for PCI were enrolled. Acute coronary syndromes were the reason
for revascularization in 549 (45.1%) patients (diabetics: 171, 46.8% vs. non-dia-
betics: 378, 44.4%; p 0.22). Multi-vessel PCI was performed in 211 (17.4%)
patients (diabetics: 66; 18.1% vs. non-diabetics: 145; 17.0%, p¼0.6). As compared
with non-diabetics, diabetics were older (67.210.5 vs. 64.811.0, p<0.001), more
often female (25.5% vs. 18.4, p¼0.05) or hypertensive (87.3 vs. 72.3, p<0.001)acts/POSTER/Bare Metal and Drug-Eluting Stent Studies B67
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Smore often presented with prior percutaneous or surgical revascularization (46.0%
vs. 37%, p¼0.003). Of the 365 diabetics, 101 (27.6%) were ITDM. ITDM patients
were more often female (35.6% vs. 21.6, p¼0.006) and with a history of prior MI
(50.0% vs. 31.8%, p¼0.001) compared to NITDM. At 12-months follow-up, the
cumulative incidence of cardiac death, TLR and MI in patients with diabetes was
comparable to that of non-diabetics (3.7% vs. 5.0%, p¼0.417). The ITDM patients
demonstrated a higher, but non-signiﬁcant, incidence of the composite end-point
compared to NITDM (4.4% vs. 3.4%, p¼0.70). The incidence of deﬁnite/probable
stent thrombosis was similar between diabetics (2/365; 0.5%) and non diabetics (5/
851; 0.6%).
Conclusions: In this multicenter registry of patients suitable for PCI, the R-ZES
resulted as safe and effective in diabetic and non-diabetic patients at 1-year follow-up.
Among diabetics, patients with ITDM are associated with a higher, but not signiﬁcant,
incidence of adverse events than patients with NITDM.Variable N=385
Preprocedure
- Lesion length, mm 13.17 [8.97, 18.73]
- Reference diameter, mm 2.73 [2.43, 2.99]
- MLD, mm 0.74 [0.44, 1.02]
- %DS 72.2 [61.8, 83.8]
Postprocedure (in-stent analysis)
- MLD, mm 2.60 [2.31, 2.88]
- %DS 7.4 [4.7, 11.6]
- Acute gain, mm 1.88 [1.49, 2.24]TCT-211
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Background: The safety and efﬁcacy of stenting followed by delivery of paclitaxel
via balloon coating in comparison with stent-polymer matrix was not established.
Therefore we compared clinical and angiographic results of paclitaxel eluting stenting
(PES) with bare metal stenting and paclitaxel coated balloon post-dilation
(BMS+PCB) for de novo coronary lesions.
Methods: In this multicenter, prospective, non-inferiority trial 202 patients with stable
or unstable angina and at least one signiﬁcant coronary artery lesion (>50% diameter
stenosis, type A, B1 and B2) were randomized in 1:1 ratio to PCI with PES (Coroﬂex
Please, B.Braun) or BMS+PCB (Coroﬂex + Sequent Please, B.Braun). Clinical
follow-up was obtained at 9 months in all patients, whereas angiographic in a subset of
94.
Results: Patients baseline characteristics were well balanced between groups. At 9
months, in-stent late lumen loss in PCB+BMS were comparable and non-inferior to
PES (0.210.5 vs. 0.300.7mm respectively, pnon-inf<0.05). Clinically, the
incidence of MACCE (7.0 vs. 6.9%, HR¼1 95%CI:0.3-2.8; p¼0.99), comprising
of occurrence of myocardial infarction (4.9 vs. 3.0% HR¼1.62 95%CI:0.4-6.5;
p¼0.32), target lesion revascularization (6.9 vs. 5.0%, HR¼1.42 95%CI: 0.4-4.4;
p¼0.54) and stent thrombosis (ST: 5.9 vs. 3.8% HR¼2.01 95%CI: 0,5 to 7,4) was
similar between PCB+BMS and PES respectively. In PCB+BMS when compared
to PES most ST occurred early (5.0 vs. 1.0%; p¼0.10), whereas in PES - late (0.9
vs. 2.8% p¼0.18). There were no deaths or cerebro-vascular accidents in both
groups.
Conclusions: Revascularization strategy with PCB+BMS is an alternative to PES
with regard to neointimal hyperplasia, however the incidence of early ST raises safety
concerns.B68 JACC Vol 62/18/Suppl B j October 27–November 1, 2013TCT-212
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Background: The novel BioMime drug-eluting stent (Meril Life Sciences Pvt. Ltd.,
Gujarat, India) incorporates a L605 cobalt-chromium metallic platform that combines
ultra-thin struts (65mm) with hybrid cell design and a bioabsorbable co-polymer
(PLLA/PLGA) formulation (2mm thickness) which carries and releases sirolimus in
a dosage of 1.25mg per mm2 of stent surface area. Our objective was to report the
angiographic ﬁndings of the BioMime sirolimus-eluting stents (SES) tested in the
meriT-1 and -2 clinical trials.
Methods: 280 pts with 385 de novo lesions located in native vessels were prospec-
tively enrolled in 2 non-randomized studies in India, including the ﬁrst-in-man, single
center meriT-1 trial (30 patients/lesions) and the subsequent multicenter meriT-2 trial
(250 pts/355 lesions). Angiographic follow-up was assigned at 8 months. QCA
analysis was performed at an independent angiographic core lab.
Results: LAD was the target vessel in 47%, 16.4% had signiﬁcant calcium, 78.4%
were eccentric, 4.9% had ulcer and pre-TIMI ﬂow 3 was found in 87.5%. Most lesions
were classiﬁed as highly complex (type B2/C in 74.8%). Predilatation was performed
in 91%, the study stent was implanted in 100%, an additional study stent was
implanted in 6%, and 60% had postdilatation; also, ﬁnal TIMI 3 ﬂow was achieved in
99.5%. QCA results are shown in the Table. Binary restenosis was found in 5.7%
(4.5% in-stent) including focal pattern (type-I) in most cases (4.8%).Follow-up at 8 months (in-stent analysis) N¼335 (87%)
- MLD, mm 2.40 [2.05, 2.71]
- %DS 11.8 [7.4, 19.2]
- Late lumen loss, mm 0.12 [0.05, 0.30]Conclusions: In this subanalysis of the combined meriT-1 and -2 trials, the novel
BioMime SES demonstrated efﬁcacy in the treatment of complex de novo coronary
lesions, as demonstrated by the relatively low median in-stent late lumen loss (a
surrogate of neointimal hyperplasia) at 8-month angiographic follow-up (87%). In
addition, in-stent binary restenosis was low (<5%) and associated with focal pattern in
the majority of cases.j TCT Abstracts/POSTER/Bare Metal and Drug-Eluting Stent Studies
